BioAgilytix Announces Acquisition of Boston-Based Clinical Research Organization Cambridge Biomedical

Highly Complementary Transaction Strengthens BioAgilytix’s Ability to Support All Phases of Biologics Development; Adds to Growing Cell & Gene Therapy Expertise; Increases Laboratory Capacity; Expands Team of Seasoned Bioanalytical Scientists; Broadens Geographic Reach

NOVEMBER 4, 2019—Durham, NC—BioAgilytix, a leading provider of large molecule bioanalytical testing services, today announced that it has acquired Cambridge Biomedical, a contract research organization based in the Cambridge area of Massachusetts, which also specializes in large molecule bioanalysis. The transaction expands BioAgilytix’s global footprint into the heart of the world’s major biotech center, and adds further capacity by joining Cambridge Biomedical’s CLIA-certified, CAP-accredited, and GLP-compliant facility with its GxP laboratories in Durham, North Carolina and Hamburg, Germany. It also grows BioAgilytix’s premier team to more than 400 employees worldwide, bringing on board Cambridge Biomedical’s seasoned bioanalytical scientists to complement and further enhance BioAgilytix’s world-class expertise in biomarkers, immunogenicity, cell-based assays, and pharmacokinetics to support all phases of biologics development. Cambridge Biomedical has particularly extensive capabilities in kit production as well as a premier molecular suite equipped with the latest generation of PCR platforms, both of which will be immediately available to BioAgilytix’s customers.

“We’re proud to have Cambridge Biomedical join BioAgilytix in our collective mission to serve customers’ evolving and expanding bioanalytical needs,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “Our companies have many synergies, both exclusively focused in large molecules and today supporting development of some of the most innovative and complex biologics, including cell and gene therapeutics. We also share the same commitment to quality and service, which has allowed both companies to build a strong scientific track record and impressive customer base. Together we will be able to offer the same premier scientific solutions and quality results, but on a larger scale. Our customers will now have access to additional scientific resources and platforms in the Cambridge area of Massachusetts, which is a hotbed of biotech innovation, and Cambridge Biomedical’s customers will be able to leverage BioAgilytix’s premier labs in the Research Triangle area of North Carolina and in Hamburg, Germany to seamlessly support large and global studies.”

“As we were considering the best way to enable Cambridge Biomedical to continue on its strong growth trajectory, it became clear that we wanted a partner – one as committed to upholding our high scientific standards and ‘people first’ values,” said Barbara Osband, Founder and Chief Executive Officer of Cambridge Biomedical. “Having personally spent more than 18 years building our business and creating a culture that recognizes being in the health care industry mandates a special level of competence, caring, and integrity, I was thrilled to merge with BioAgilytix whose value systems mirror our own. I couldn’t be more confident placing Cambridge Biomedical in the capable hands of BioAgilytix’s leadership team.”

“We have found in BioAgilytix a company that cares as deeply about scientific excellence as we do, and that shares our steadfast commitment to both our customers and employees,” said Linda Robbie, Ph.D., Senior Vice President of Science and Laboratory Operations at Cambridge Biomedical. “Throughout its 22-year history, Cambridge Biomedical has maintained a stellar reputation for high scientific and service standards, and we’ve experienced impressive growth in the last few years. We wanted a partner to help take our team to the next level, continuing to cultivate Cambridge Biomedical’s success by building on the core values that have brought us to where we are today. I couldn’t be happier to have our team join BioAgilytix, and I’m excited to see where we will go from here together. I know our customers on both sides will see many benefits from the uniting of our companies.”

Cambridge Biomedical was represented by Fairmount Partners throughout this transaction.


About BioAgilytix
BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina’s Research Triangle area and Hamburg, Germany, BioAgilytix provides biomarker, immunogenicity, cell-based assay, and PK services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e. product release testing, stability testing, etc.).

BioAgilytix’s team of highly experienced scientific and QA professionals ensures high quality science, data integrity, and regulatory compliance through all phases of clinical development, and is a trusted partner to many of the top global pharmaceutical and biotech companies. For more information, visit

About Cambridge Biomedical
Founded in 1997, Cambridge Biomedical is a specialized clinical research organization serving the diverse requirements of the biopharmaceutical/pharmaceutical and diagnostic markets, utilizing its multi-platform laboratory science capabilities and state-of-the-art systems and procedures to deliver timely, accurate results.

Cambridge Biomedical provides clients with assay development, assay validation, and testing services in support of their clinical trial and pharmaceutical development objectives, serving as a trusted advisor to deliver value-added services and expertise to help advance breakthroughs in patient care.

Media Contact:
Carla Nieser
Vovéo Marketing Group
610.240.0400, x 118

"Immuno Oncology and the BTK Occupancy Assay"

This past December, Cambridge Biomedical held its Winter Scientific Luncheon titled “Immuno Oncology and the BTK Occupancy Assay” - at the Mass Biotech Council in Kendall Square. Click here for the video presentation. If you would like a copy of the slide deck, please email If Cambridge Biomedical can assist you with your interest in the BTK assay please contact us.

Video from Cambridge Biomedical’s Second Biannual Scientific Meeting – December 12, 2017

Cambridge Biomedical hosted its second annual scientific meeting this past December.  Forty scientists from the Greater Boston area attended the event focusing on the Microbiome.  It is Cambridge Biomedical’s pleasure with the approval of Synlogic to share Dr. Millet’s presentation. Once you have enjoyed the talk and would like to know how Cambridge Biomedical can contribute to your efforts please submit your request at

“Synthetic Biotic™ Medicines: A New Class of Treatments.”

Dr. Yves Millet, Synlogic Therapeutics.


The fields of synthetic biology and microbiome research have expanded greatly over the last decade enabling the development of new therapeutic strategies using engineered microbes that operate from within the gut. Synlogic is pioneering the development of a novel class of engineered, living drugs, called Synthetic Biotic™ Medicines, that can be designed to correct missing or dysfunctional metabolic activities or deliver effectors in the GI tract, with the potential to treat a wide range of diseases. The opportunities and challenges of this new therapeutic platform and the results obtained with two lead programs for the treatment of Urea Cycle Disorder and Phenylketonuria will be presented.

About Dr. Millet

Dr. Yves Millet is a Lead Scientist at Synlogic, located in Cambridge, MA, focused on the development of engineered probiotics for the treatment of rare metabolic disorders. Previously, he was a Scientist at Indigo (formerly known as Symbiota), a plant microbiome company based in Boston. Dr. Millet completed a Postdoctoral Fellowship in the laboratory of Dr. Matthew Waldor at Harvard Medical School where he studied the pathogenesis of Vibrio cholerae, the causative agent of cholera. He received his Ph.D. in Molecular and Cell Biology from Strasbourg University, France and carried out his graduate research in the laboratory of Prof. Frederick Ausubel at The Massachusetts General Hospital.

The development of cellular therapies could lead to advances in the treatment of trauma and critical care injuries

In recent years, significant advances have been made in treating those who have suffered severe hemorrhage and trauma, with the methods used to stop bleeding and resuscitate patients having made the largest strides. However, we currently provide little more than supportive care to those who survive the initial trauma. Since trauma is the leading cause of death for those aged 1 through 44, it is important that we develop therapeutic treatments for intermediate and long-term recovery.

An emerging area of particular interest in the treatment and rehabilitation of trauma survivors is the use of cellular therapy (CT), which can potentially be used to both prevent secondary injury and support the repair of injured tissues. Recent studies conducted with both animals and humans have shown that CT may be effective in treating conditions such as traumatic brain, spinal cord, and acute kidney injuries, organ failure, and burns, along with healing soft-tissue damage in the extremities.

Currently, there are two types of CT with significant potential for long-term healing. One is adult multipotent cells, which have the ability to replicate a limited number of differentiated cell types. The other type is pluripotent stem cells, which have an unlimited capacity for self-renewal and can also differentiate into any kind of cell in the body. Adult multipotent cells are more useful for the prevention of future injury and repair of injured tissues, whereas pluripotent cells are better suited for the replacement of cells in lost or injured tissue.

It’s evident that research involving CT could lead to a significant difference in how physicians care for patients healing from trauma, as well as how well these patients are able to return to a sense of normalcy after suffering from such extreme injuries.

For more information on the use of CT for trauma treatment, check out this article recently published in PlosMedicine.

By: Rebecca Yount

Meet and Greet the new VP of Scientific Affairs

Please join us to enjoy an informal breakfast welcoming Linda back to Boston. Meet Dr. Robbie and find out more about her vision to move Cambridge Biomedical into the next level of CRO/Sponsor partnerships. Share your needs and wishes directly to her, our top scientific executive. Take a look at her bio on our website and see how she is uniquely positioned to achieve this goal and provide drug development and medical diagnostic organizations superior support.

For full event details, see here!

RSVP to Eric Wexler:

Eric J. Wexler, M.B.A. Business Development Director - New England

Office: 617.456.0734 ~ Cell: 617.877.2489